Pulse Biosciences Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call for February 22, 2021

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the fourth quarter and full year 2020 after market close on Monday, February 22, 2021. Company management will host a corresponding conference call beginning at 1:30pm PT.

Investors interested in listening to the conference call may do so by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. To learn more, please visit pulsebiosciences.com.

To stay informed about the CellFX System, please visit CellFX.com and sign up for updates.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210212005120/en/

Investors:
Pulse Biosciences
Sandra Gardiner, EVP and CFO
510.241.1077
[email protected]
or
Gilmartin Group
Philip Trip Taylor
415.937.5406
[email protected]

Media:
Tosk Communications
Nadine D. Tosk
504.453.8344
[email protected]

Source: Pulse Biosciences, Inc.

You May Also Be Interested In

• Cross River Continues Strong Momentum with Over $200MM in Commercial Banking Group Real Estate Loan Originations
• Atlanta Community Food Bank Opens New Community Food Center in Jonesboro
• Actor Glen Powell Kicks Off Next Chapter of the Ram Truck Brand With the Launch of All-new 2025 Ram 1500 RHO as Part of the Full Lineup of Off-road Trucks